Bio-Techne Corporation

Bio-Techne Corporation is an American life sciences company that develops, manufactures, and sells purified proteins, antibodies, immunoassays, spatial biology instruments, and molecular diagnostic products to academic researchers, pharmaceutical companies, and clinical laboratories worldwide, generating $1.22 billion in revenue in fiscal 2025.

This is a story about a high-quality life sciences franchise whose stock has been cut by more than half — from above $130 in late 2021 to roughly $51 today — as the market has progressively stripped away the premium multiple it once awarded. The underlying business has not broken: Bio-Techne still holds leading positions in recombinant proteins, commands ~70% adjusted gross margins, and converts over 20% of revenue into free cash flow. But organic growth has decelerated into the low single digits, GAAP earnings have been buried under a cascade of non-recurring charges, and a contractual obligation to acquire the remainder of Wilson Wolf for roughly $1 billion — due by the end of calendar 2027 — introduces an idiosyncratic financing question that hangs over the stock. The market is pricing the business as though growth will never return and the Wilson Wolf obligation will be a burden rather than a catalyst.

The file turns on a single question: whether Bio-Techne's portfolio repositioning — shedding low-growth animal-derived products, divesting a non-strategic CLIA lab business, restructuring manufacturing, and orienting toward spatial biology and cell therapy workflows — can restore organic growth to a level that justifies something better than a no-growth multiple. The answer depends less on macro conditions than on execution within businesses Bio-Techne already owns.